With customers, physicians and nurse educators ticked off at MiniMed due to the changes made to customer service and Disetronic a non-factor due to FDA issues, the door was opened for Animas and the Cosmo to grab some market share. At the time each system was considered innovative and a possible threat to the Medtronic stranglehold on the insulin pump market. Although neither Animas nor Cosmo became a serious threat they did grab some very valuable market share, market share that made Cosmo enough a threat to become the target of Medtronic lawsuit and push Animas into the hands of Johnson and Johnson (NYSE:JNJ).